Covaxin gets emergency use approval for children aged 2-18 years

Subject Expert Committee ( SEC) has recommended granting an emergency use authorisation to Bharat Biotech's #Covaxin for children aged between 2-18. The SEC has submitted its recommendation to the Drugs Controller General of India (DCGI) for final approval. Bharat Biotech had last week submitted Phase 2/3 clinical trials data of children's trials to the DCGI.